Description
Pain Management Conference
Saturday, January 25, 2025
Scratching the Surface: A Review of Pain Pathophysiology and
Pharmacology
8:00-9:30am C/G/T
Satya Yaramati, PharmD, PGY2 Pain & Palliative Care Pharmacy Resident, UF Health Jacksonville
Upon completion of this activity, pharmacists will be able to: Describe
the pathophysiology of nociceptive, neuropathic, and central pain;
Collect a detailed pain history and appropriately assess a patient’s pain;
Summarize the indications, mechanism of action, dosing, side effects and
clinical pearls for various agents used to treat pain; Identify opportunities
for intervention regarding pharmacologic pain management therapy.
UAN: 0675-0000-25-001-L08-P
Upon completion of this activity, technicians will be able to:
Describe the various types of pain; Summarize the indications
and side effect profile of different pain agents; Recognize
opportunities for intervention regarding pain management therapy.
UAN: 0675-0000-25-001-L08-T
Recognizing the Danger Zone: Strategies and Considerations in Adjusting
Pain Management Treatment Regimens in Chronic Pain Management
9:30-11:00am C/G/T
Robin Moorman Li, PharmD, BCACP, NBC-HWC, Assistant Director Jacksonville Campus, Clinical Associate Professor, University of Florida,
College of Pharmacy
Upon completion of this activity, pharmacists will be able to: Outline
common steps to create a comprehensive pain management plan; Describe
reasons why commonly used analgesic regimens must be adjusted due to
patient related and agent related variables; Recommend adjustments to
pain management treatment regimens in organ dysfunction; Demonstrate a
stepwise approach for opioid conversions; List important patient education
points on opioid conversions and proper use of breakthrough pain
medications.
UAN: 0675-0000-25-002-L08-P*
Upon completion of this activity, technicians will be able to: Recognize a
comprehensive pain management plan; Identify reasons why commonly used
analgesic regimens must be adjusted due to patient related and agent related
variables; Calculate dose conversions of certain opioids; List important patient
education points on opioid conversions.
UAN: 675-0000-25-002-L08-T*
A Novel Approach: Preventing & Treating Chronic Pain Due to
Obesity in the Healthcare Setting
11:15-12:45pm C/G/T
Matthew Hermenau, PharmD, CPT, NBC-HWC, Inpatient Pain Stewardship
Clinical Pharmacist, Jackson Memorial Hospital
Upon completion of this activity, pharmacists will be able to: Explain the
rising correlation between degenerative joint disease, obesity, and chronic
pain in the United States; Compare the current pitfalls of the healthcare model
for chronic pain due to obesity, and introduce a new hybrid model of inpatient
and outpatient management; Identify non-pharmacologic ways to combat the
obesity crisis and subsequent chronic pain
UAN: 0675-0000-25-003-L08-P
Upon completion of this activity, technicians will be able to: Explain the
correlation between degenerative joint disease, obesity, and chronic pain in
the United States; Compare the current pitfalls of the healthcare model for
chronic pain due to obesity; Recognize non-pharmacologic ways to combat the
obesity crisis and subsequent chronic pain.
UAN: 0675-0000-25-003-L08-T
Managing Pain in Multiple Sclerosis
12:45-2:15pm C/G/T
Lillian Smith, PharmD, MDA, CPh Associate Professor of Pharmacy Practice,
FAMU College of Pharmacy
Upon completion of this activity, pharmacists will be able to: Define
Multiple Sclerosis (MS) and its current impact within the United States;
Provide an overview of the risk factors and pathophysiology associated with
MS; Identify the potential genetic, environmental, and infectious factors that
may causes the disease state; Distinguish between the primary, secondary,
and tertiary symptoms caused by multiple sclerosis; Discuss the criterion and
physical assessment involved in concluding the diagnosis of MS; Categorize
the four types of multiple sclerosis while understanding the differences
and similarities between them; Outline both non-pharmacological and
pharmacological interventions currently available for the treatment of the
disease; Illustrate health disparities and barriers to care MS patients currently
experience in maintaining the condition; Describe the role of all involved in the
management of MS while outlining potential resources utilized for additional
support.
0675-0000-25-004-L01-P*
Upon completion of this activity, technicians will be able to: Define
Multiple Sclerosis (MS); Provide an overview of the risk factors and symptoms
associated with MS; Compare and contrast between the primary, secondary,
and tertiary symptoms caused by multiple sclerosis; Categorize the four types
of multiple sclerosis; Outline both non-pharmacological and pharmacological
interventions currently available for the treatment of the disease.
UAN: 675-0000-25-004-L01-T*
Validation and Counseling of Prescriptions for Controlled
Substance & Opioids
2:30-4:30pm G/T
Joseph Cammilleri, PharmD, BCACP, CPE, Ambulatory Care Clinical
Pharmacist, Pain Management, PGY2 Pain/Palliative Care Program Director,
UF Health.
Upon completion of this activity, pharmacists will be able to: Describe
how to ensure access to controlled substances for all patients with a valid
prescription; Use the Prescription Drug Monitoring Program’s Database;
Assess prescriptions for appropriate therapeutic value; Detect prescriptions
that are not based on a legitimate medical purpose; Discuss the laws and
rules related to the prescribing and dispensing of controlled substances;
Discuss proper patient storage and disposal of controlled substances;
Discuss protocols for addressing and resolving problems recognized during
the drug utilization review; Provide education on section 381.887, F.S.,
emergency treatment for suspected opioid overdoses and on the State
Surgeon General’s Statewide Standing Order for Naloxone; Counsel patients
with opioid prescriptions; Provide available treatment resources for opioid
physical dependence, addiction, misuse, or abuse
UAN: 0675-0000-25-005-L08-P*
Upon completion of this activity, technicians will be able to: Use the
Prescription Drug Monitoring Program’s Database; Assess prescriptions
for appropriate and accurate information; Recognize the laws and rules
related to the prescribing and dispensing of controlled substances.
UAN: 0675-0000-25-005-L08-T*
Sunday, January 26, 2025
The Role of the Pharmacist in Palliative Care
8:00-9:30am C/G/T
Katie Maples, PharmD, Pain and Palliative Care Coordinator and Opioid
Stewardship Pharmacist, UF Health Jacksonville
Upon completion of this activity, pharmacists will be able to: Define
Palliative Care; Discuss the importance of defining goals of care throughout the
disease process; Recommend symptom management medication frequently
used at end of life; Identify common misconceptions related to medication
usage at end of life.
UAN: 0675-0000-25-006-L08-P
Upon completion of this activity, technicians will be able to: Define Palliative
Care; Discuss the importance of defining goals of care throughout the disease
process; Identify symptom management medications frequently used at the
end of life; Identify common misconceptions related to medication usage at
end of life.
UAN: 675-0000-25-006-L08-T
When Aging Isn’t So Fun: Pain Management, Polypharmacy and
Deprescribing in the Elderly
9:30-11:00am C/G/T
Paige Broccio, PharmD, BCPS, Clinical Pharmacy Specialist, Pain Management and Palliative Care
Upon completion of this activity, pharmacists will be able to: Describe
pharmacologic difference in the elderly population; Compare multimodal
pain management options in the elderly; Discuss potential ramifications of
polypharmacy; Assess potentially inappropriate medications in the elderly
population; Determine goals of deprescribing.
UAN: 0675-0000-25-007-L08-P*
Upon completion of this activity, technicians will be able to: Define
polypharmacy and the importance of deprescribing in the elderly; Differentiate
pharmacologic differences in the elderly population; Compare various pain
management options in the elderly.
UAN: 0675-0000-25-007-L08-T*
Overview of Buprenorphine
11:15-12:45pm C/G/T
Taylor Bunn PharmD, PGY-1 Pharmacy Resident, UF Health Jacksonville
Upon completion of this activity, pharmacists will be able to: Describe the
mechanism of action, formulations, and usual doses of buprenorphine; Display
areas of pharmacy interventions; Evaluate the effects of pharmacist managed
micro-induction; Review customized buprenorphine micro-inductions;
Showcase the beneficial effects for patients.
UAN: 0675-0000-25-008-L0-P*
Upon completion of this activity, technicians will be able to:
Recognize the usual doses of buprenorphine; Assess areas of pharmacy
interventions; Evaluate the effects of pharmacist managed micro-induction.
UAN: 675-0000-25-008-L08-T*
Abnormal Urine Drug Screen: What’s Next?
12:45-2:15pm C/G/T
Joseph Cammilleri, Pharm.D,. BCACP, CPE, Ambulatory Care Clinical Pharmacist, Pain Management, PGY2 Pain and Palliative Care Program Director, UF Clinical Assistant Professor, UF Health Jacksonville
Upon completion of this activity, pharmacists will be able to: Describe
common urine drug testing methods; Assess strategies for managing abnormal
results; Develop a strategy for tapering off opioid medications; Explain how to
transition a patient to buprenorphine.
UAN: 0675-0000-25-009-L08-P*
Upon completion of this activity, technicians will be able to: Describe
common urine drug testing methods; Research strategies for managing
abnormal results; Outline a strategy for tapering off opioid medications;
Translate the importance of transition to buprenorphine. Upon completion of
this activity, technicians will be able to: Describe common urine drug testing
methods; Research strategies for managing abnormal results; Outline a strategy
for tapering off opioid medications; Translate the importance of transition to
buprenorphine.
UAN: 0675-0000-25-009-L08-T*
Mitigation and Prevention of Medication Errors in Pharmacy Practice
2:30-4:30PM G/T
Norman P. Tomaka, BS Pharm, MS, CPh, FAPhA, Clinical Consultant Pharmacist, Consultant Pharmacy Services
Upon completion of this activity, pharmacists will be able to: Recognize
statutory responsibilities that foster ongoing pharmacy regulatory compliance;
Recognize recurring medication errors; Describe quality improvement
regulations for pharmacies licensed in Florida; Define elements of a proactive
Continuous Quality Improvement process that promotes ongoing quality;
Discuss the use of Root Cause Analysis (RCA) to enhance quality pharmacy
services and prevent errors; Describe the implementation of an action plan
to improve overall pharmacy practice quality and mitigate medication errors;
Demonstrate enactment of procedures that promote ongoing patient safety in
pharmacy practice.
UAN: 0675-0000-25-010-L05-P
Upon completion of this activity, technicians will be able to: Recognize
statutory responsibilities that foster ongoing pharmacy regulatory compliance;
Recognize recurring medication errors; Describe quality improvement
regulations for pharmacies licensed in Florida; Define elements of a proactive
Continuous Quality Improvement process that promotes ongoing quality;
Discuss the use of Root Cause Analysis (RCA) to enhance quality pharmacy
services and prevent errors; Describe the implementation of an action plan
to improve overall pharmacy practice quality and mitigate medication errors;
Outline procedures that promote ongoing patient safety in pharmacy practice.
UAN: 0675-0000-25-010-L05-T
C = Consultant CPE G = General Pharmacist CPE T = Technician CPE
